University of California, Irvine — Biomedical Watch V2

Traitements9programmes

Essais4liés

Publications9liées

SourceDBlocale

Traitements

9

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
NortriptylineTinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. Despite too many research projects on finding the mechanism of tinnitus, its pathophysiology remains poorly understood. It is well understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influence the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, the investigators intend to use medications for patients with acute tinnitus to decrease the impact of tinnitus in their daily lives and activities. There are some studies on medications treating tinnitus; however, there are few randomized clinical trials to prove the efficacy of the treatment. The frequency and loudness of tinnitus will be measured before and after the course. Functional MRI of the brain will be obtained to view any changes that may occur before and after the treatment.	Migraine	Phase 4	À vérifier	United States	À vérifier
nortriptyline + topiramateMeniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.	Migraine	Phase 4	Traitement symptomatique	United States	À vérifier
paroxetineThis is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.	Migraine, SEP	Phase 4	Traitement symptomatique	United States	À vérifier
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal CarcinomatosisThis is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.	Cancer	Non applicable	À vérifier	United States	À vérifier
VerapamilTinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. Despite too many research projects on finding the mechanism of tinnitus, its pathophysiology remains poorly understood. It is well understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influence the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, the investigators intend to use medications for patients with acute tinnitus to decrease the impact of tinnitus in their daily lives and activities. There are some studies on medications treating tinnitus; however, there are few randomized clinical trials to prove the efficacy of the treatment. The frequency and loudness of tinnitus will be measured before and after the course. Functional MRI of the brain will be obtained to view any changes that may occur before and after the treatment.	Migraine	Phase 4	À vérifier	United States	À vérifier
paroxetineThis is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.	SEP	Phase 3	Traitement symptomatique	Canada	À vérifier
NortriptylineTinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. Despite too many research projects on finding the mechanism of tinnitus, its pathophysiology remains poorly understood. It is well understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influence the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, the investigators intend to use medications for patients with acute tinnitus to decrease the impact of tinnitus in their daily lives and activities. There are some studies on medications treating tinnitus; however, there are few randomized clinical trials to prove the efficacy of the treatment. The frequency and loudness of tinnitus will be measured before and after the course. Functional MRI of the brain will be obtained to view any changes that may occur before and after the treatment.	Migraine	Phase 4	À vérifier	United States	À vérifier
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal CarcinomatosisThis is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.	Cancer	Non applicable	À vérifier	United States	À vérifier
nortriptyline + topiramateMeniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.	Migraine	Phase 4	Traitement symptomatique	United States	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
nortriptyline + topiramate	Migraine	Phase 4	NCT05582837	Treatment of Meniere's Disease With Migraine Medications	RECRUITING
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis	Cancer	Non applicable	NCT05844865	Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis	RECRUITING
Nortriptyline	Migraine	Phase 4	NCT06799169	Management of Acute Tinnitus With Migraine Medications	ACTIVE_NOT_RECRUITING
paroxetine	SEP	Phase 3	NCT00291148	Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain	COMPLETED

Publications

9

Molécule	Indication / population	Titre	Journal	Date
Verapamil		An artificial model of ATP-binding cassette mediated transport.	Colloids and surfaces. B, Biointerfaces
Nortriptyline		Exploring health professionals' perspectives and preferences in the treatment of post-stroke fatigue and mental health disorders: an Australian qualitative vignette-based study.	The International journal of pharmacy practice
paroxetine		Psychopharmacological treatment of patients with heart failure: A narrative review of antidepressants and anxiolytics.	Current problems in cardiology
paroxetine		Redox modulation contributes to the antidepressant-like and neuroprotective effects of 7-chloro-4-(phenylselanyl)quinoline in an Alzheimer's disease model.	Redox report : communications in free radical research
paroxetine		Modelling post-traumatic stress disorder-major depressive disorder comorbidity in rats: impaired α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor signalling is consistent with synergistic behavioural and cognitive deficits.	European journal of psychotraumatology
paroxetine		The impact of fluoxetine on the aversive effects of lysergic acid diethylamide.	Experimental and clinical psychopharmacology
paroxetine		Xiaoyao San exerts antidepressant effects via the gut microbiota-brain axis: An integrative fMRI and multiomics study.	Journal of pharmaceutical and biomedical analysis
paroxetine		Drug-induced dysphagia: Analysis of age and time of onset profiles using a Japanese pharmacovigilance database.	International journal of clinical pharmacology and therapeutics
paroxetine		Effects of antidepressant administration on physical performance and perceived exertion in athletes: systematic review and meta-analysis.	International journal of clinical pharmacy